Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

First-in-human Phase 1/2 Trial of EGL-001 in Adult Patients with Selected Advanced And/or Metastatic Solid Tumors

NCT06622486 is registered in ClinicalTrials.gov with Egle Therapeutics as lead sponsor.

NCT NCT06622486
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06622486 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
First-in-human Phase 1/2 Trial of EGL-001 in Adult Patients with Selected Advanced And/or Metastatic Solid Tumors
Lead sponsor
Egle Therapeutics
Phase
Phase 1/2
Overall status
Recruiting
Start date
September 27, 2024
Completion date
January 23, 2027
Enrollment
50 (estimated)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumor, adult